Caribou Biosciences, IDT Announce Agreement
News Feb 24, 2016
Caribou Biosciences, Inc. and Integrated DNA Technologies, Inc. (IDT) have entered into a non-exclusive license agreement under which Caribou has granted IDT worldwide rights to commercialize CRISPR-Cas9 reagents under Caribou’s intellectual property. The license is subject to a research use limited label.
“We are proud to partner with Integrated DNA Technologies, a prominent leader in the field of nucleic acid–based technologies,” said Rachel Haurwitz, Ph.D., President and Chief Executive Officer of Caribou. “This partnership will help provide researchers with the tools they need to conduct effective CRISPR-Cas9 research.”
Joseph Walder, M.D., Ph.D., President and Chief Executive Officer of IDT, said, “IDT is excited to be the first genomics company to have reached this agreement with Caribou, a recognized leader in the field of CRISPR-Cas9 research. This license allows us to deliver the entire spectrum of products for CRISPR-Cas9 genome editing, solidifying our position at the forefront of this groundbreaking technology.”
IDT’s CRISPR-Cas9 reagents will be used by customers conducting biological research across a broad range of scientific areas such as drug discovery, plant biology, and genomics. IDT’s CRISPR-Cas9 reagents will provide researchers with the ability to edit genomic DNA precisely and efficiently.
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.